| Document |
Document Title |
|
WO/2018/050663A1 |
The present invention relates to novel compounds which effectively inhibit the melanin synthesis in human melanocytes and are thus suitable for the treatment of senile lentigines, for smoothening skin color irregularities and/or for ligh...
|
|
WO/2018/044012A1 |
The present invention relates to a peptide having anticancer activity, and a cancer preventing and treating pharmaceutical composition, functional health food composition and functional cosmetic composition containing same as an active i...
|
|
WO/2018/036942A1 |
The invention provides novel compounds having the general formula (I): (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, X and R11 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2018/035610A1 |
The present invention provides 18F-labeled amino acids or derivatives thereof having formula (I) and methods of making same, which can be suitable for PET imaging: (Formula (I)).
|
|
WO/2018/035519A1 |
The present invention relates to compositions and methods for the treatment or prevention of autoimmune diseases such as demyelination disorders. The invention includes a composition comprising a peptide antigen comprising at least one b...
|
|
WO/2018/034356A1 |
The present invention provides a peptide comprising an amino acid sequence represented by any of formulas (I)-(III), and a conjugate comprising the peptide and a functional part. (I) The amino acid sequence (X1) [D]P[D](X2)[D] (in the se...
|
|
WO/2018/034901A1 |
Disclosed are methods of making elamipretide (MTP-131), a peptide compound with therapeutic potential for treating various mitochondrial myopathies. The synthesis of the peptide can be achieved via the use of N-carboxyanhydride-modified ...
|
|
WO/2018/031690A1 |
Compounds and compositions are disclosed in which a Drug Unit is linked to a targeting Ligand Unit through a self-stabilizing Linker Unit from which a drug compound or active drug moiety is released at the targeted site of action. Method...
|
|
WO/2018/028634A1 |
Salts of compound (I) and pharmaceutically compositions thereof, specially a base addition salt, an acid addition salt of compound (I) and a pharmaceutically composition thereof, future the use of the compound and the pharmaceutical comp...
|
|
WO/2018/024645A1 |
The present invention relates to a process for preparation of Carfilzomib of formula (I).
|
|
WO/2018/018863A1 |
Disclosed are a mild and efficient preparation method for an α-acyloxy alkenyl amide compound and a use thereof in the synthesis of an amide and a polypeptide. The α-acyloxy alkenyl amide compound is obtained by an addition reaction of...
|
|
WO/2018/022937A1 |
The present invention provides novel peptide inhibitors of interleukin-23, and related methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, Crohn's disea...
|
|
WO/2018/019196A1 |
A substituted boric acid compound, a pharmaceutical composition comprising same, and an application thereof. The substituted boric acid compound is a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable s...
|
|
WO/2018/022866A1 |
The present invention provides a compound of formula (I) or a salt thereof and their use as a biomarker in assessing or monitoring kidney function in a subject, determining predisposition to developing reduced kidney function, classifyin...
|
|
WO/2018/023028A1 |
Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with synucleinopathy and for measuring synucleinopathy progression or status. Test kits for diagnosis of an indiv...
|
|
WO/2018/012901A1 |
The present invention relates to a pharmaceutical composition for cell protection containing cyclo histidine-proline (cyclo His-Pro, CHP) as an active ingredient. The pharmaceutical composition for cell protection containing cyclo histid...
|
|
WO/2018/006667A1 |
Disclosed are antihypertensive peptides and antihypertensive proteins and a use thereof. The amino acid sequences of the antihypertensive peptides are respectively TTW, VHW and KAKW, and the amino acid sequences of the antihypertensive p...
|
|
WO/2018/007495A1 |
The present invention relates to compounds of formula (I) and compositions comprising them for use in enhancing umami taste and/ or saltiness of a food product.
|
|
WO/2018/007496A1 |
The present invention relates to compounds and compositions for use in enhancing flavor and/or saltiness of a food product. Particularly, the present invention relates to compounds of the general formula I) and compositions comprising them.
|
|
WO/2018/008902A1 |
The present invention relates to a psoriasis-induced animal model and a use thereof and, more particularly, to: a psoriasis-induced animal model transformed such that a Pellino homolog 1 (Peli1) gene is overexpressed according to the adm...
|
|
WO/2018/000079A1 |
Novel cyclic peptide GHRP-6 analogs of formula (I): (I) or pharmaceutically acceptable esters or salts thereof, are described. These cyclic peptide GHRP-6 analogs may be used for modulating CD36 activity, for example for the treatment of...
|
|
WO/2018/001332A1 |
A compound having an inhibitory activity against a mutant isocitrate dehydrogenase, a preparation method therefor and use thereof, particularly a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or an ena...
|
|
WO/2018/004281A2 |
Disclosed are a tranexamic acid-peptide having a skin whitening effect and skin whitening activity with excellent thermal stability and time stability, which is capable of inducing return to healthy skin and whitening effect through skin...
|
|
WO/2018/001273A1 |
Provided are a peptide or a salt thereof, and a preparation method therefor. The peptide may be selected from VVYP, AVLP, IGFP, LLIIVP and STAP. The preparation method comprises steps as follows: using a resin as a starting material, lin...
|
|
WO/2018/005332A1 |
Endomorphin-2 and tetrapeptide derivatives thereof are described. Pharmaceutical or cosmetic compositions containing endomorphin-2 or a tetrapeptide derivative thereof are therapeutically effective to treat, improve or prevent pain in hu...
|
|
WO/2017/223098A1 |
Compositions comprising bis(tryptophan) derivatives are provided that act as antimicrobials. Also provided are methods for reversing antibiotic resistance in a bacterium, or recovering or enhancing antimicrobial activity of an antibiotic...
|
|
WO/2017/219808A1 |
Provided are a compound as shown in formula (I) usable as a hepatitis C virus inhibitor, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, usable to treat hepatitis C virus (HCV) infections or hepa...
|
|
WO/2017/217535A1 |
Provided is a novel peptide having an ACE inhibitory activity. More particularly, provided is a tripeptide comprising Leu-Arg-Ala.
|
|
WO/2017/217728A1 |
The present invention relates to: a composition for promoting angiogenesis, a pharmaceutical composition for preventing or treating angiogenesis-dependent diseases, and a quasi-drug and cosmetic composition for skin regeneration, all of ...
|
|
WO/2017/217855A1 |
Disclosed are geminoid peptide-like compound according to Formula (I): R1 - C(=0) - Zn - NR3 - R2 in which R1 and R2 are each independently saturated, partly saturated or unsaturated, straight, branched or cyclic alkyl chains, wherein R1...
|
|
WO/2017/216177A1 |
The peptide has from 3 to 10 amino acids comprising at least the sequence K*(Ac)GH or K*(Ac)HG and may further comprise an N-terminus modification, preferably an acylation, and/or a C-terminus modification; K* is selected from the group ...
|
|
WO/2017/211818A1 |
The present invention relates to a compound of formula (I), wherein X is C=0, C=S or B-OH; Y is an electrophile and Z is a leaving group, or Y══Z is an electrophile; R1 comprises or consists of (a) (i) a first group binding to a prot...
|
|
WO/2017/214534A1 |
The invention provides a copper-mediated process for making compounds according to Formula (I): that are the macrocyclic scaffolds of the arylomycin class of biologically active compounds, where R1, R2, R3, RA1, RA2, RA3, B, G1, G2, PG, ...
|
|
WO/2017/214076A1 |
The present invention describes rhomboid protease inhibitors having high specificity and inhibition characteristics providing novel antibiotics, anti-malarial pharmaceutical agents, and provides a strategy for designing RiBns (rhomboid-i...
|
|
WO/2017/211272A1 |
The present invention provides a phenyl propanamide derivative as represented by formula (I), a manufacturing method of the derivative, application of the derivative as a κ-opioid receptor (KOR) agonist, and application of the derivativ...
|
|
WO/2017/207546A1 |
The present invention relates to washing or cleaning compositions, preferably liquid washing compositions, comprising at least one protease, at least one compound of the formula (I) and/or of the formula (II) that acts as a protease inhi...
|
|
WO/2017/209805A1 |
A variety of hydrophobically modified polypeptoids are provided. The hydrophobically modified polypeptoids can include a polyamide backbone having a random copolymer of two or more different types of repeat units, where one or more of th...
|
|
WO/2017/205392A1 |
The present invention provides polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein. The invention also provides methods of maki...
|
|
WO/2017/204606A1 |
The present invention relates to a cytosol-penetrating antibody and a use thereof, and specifically, to a light chain variable region and/or heavy chain variable region positioned in a cytosol, a cytosol-penetrating antibody containing s...
|
|
WO/2017/201624A1 |
A transdermal formulation which can be applied to the skin as a latex-free hypoallergenic adhesive patch or transdermal delivery cream using a combination of glutathione, Vitamin D, glycol, sodium bicarbonate and base cream resilient in ...
|
|
WO/2017/201433A1 |
The disclosure provides methods of preventing or treating mitochondrial myopathy in a mammalian subject, reducing risk factors associated with mitochondrial myopathy, and/or reducing the likelihood or severity of mitochondrial myopathy. ...
|
|
WO/2017/197386A1 |
Methods for diagnosing, treating, and monitoring the treatment of mucormycosis are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having m...
|
|
WO/2017/193562A1 |
A water soluble rapamycin derivative modified by glutathione and represented by formula I and a preparation method therefor. Definition to R1 and R2 is described in the specification. A compound represented by the formula I can be used f...
|
|
WO/2017/193757A1 |
Provided are a water-soluble Epothilone derivative represented by formula (I), a preparation method therefor and an intermediate thereof, and an application thereof in preparation of drugs for inhibiting growth of tumor cells.
|
|
WO/2017/197303A1 |
This disclosure is directed to novel apicidin methods and compositions for the inhibition of quorum sensing in bacterial infections and novel apicidin methods and compositions for treating a staphylococcal infection.
|
|
WO/2017/181437A1 |
Provided is a non-amino acid method for chemical total synthesis of polypeptides. Said non-amino acid method for chemical total synthesis of polypeptides uses as a raw material ketoamide compounds, which are synthesized into a polypeptid...
|
|
WO/2017/184520A1 |
Embodiments of the invention include compounds and compositions thereof to inhibit protease activated receptor-4. Also described are methods of preparation of compositions and methods for treating diseases related to thrombotic disorders...
|
|
WO/2017/184670A2 |
Provided are methods for treating Zika virus infections by administering a compound of Formula I, Formula II, Formula III, or Formula IV, or combinations thereof.
|
|
WO/2017/179838A1 |
The present invention provides a peptide having anti-inflammatory activity, composed of an amino acid sequence of a sequence listing of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3. The peptide inhibits the expression of inflammatory cytok...
|
|
WO/2017/178333A1 |
The present invention discloses retro-inverso peptides and pharmaceutical composition containing them. The peptides of the invention prevent key events occurring during the metastatic process, i.e. invasion of the extracellular matrix, f...
|
